Abzena, a CDMO for complex biologics and antibody drug conjugates (ADCs), has appointed Thomas Castellano, Chief Financial Officer. In a statement, the company said that Castellano is a proven leader in the CDMO industry, with more than 20 years of experience in corporate finance and capital markets, underpinned by a strong foundation in biotechnology industry finance. He joins Abzena from Catalent, where he spent 15 years in financial leadership roles of increasing responsibility, most recen...